Clearmind Medicine (NASDAQ:CMND) Posts Quarterly Earnings Results

Clearmind Medicine (NASDAQ:CMND) released its quarterly earnings data on Monday. The company reported ($6.78) earnings per share (EPS) for the quarter, Zacks reports.

Clearmind Medicine Stock Performance

Shares of Clearmind Medicine stock traded up $0.03 during trading hours on Monday, reaching $3.37. The company’s stock had a trading volume of 102,555 shares, compared to its average volume of 1,144,939. The company’s 50 day simple moving average is $6.22 and its 200 day simple moving average is $16.48. Clearmind Medicine has a one year low of $2.10 and a one year high of $524.00. The stock has a market cap of $3.43 million, a P/E ratio of -0.02 and a beta of 0.64.

Insiders Place Their Bets

In related news, major shareholder Financial Lp Hrt sold 225,191 shares of Clearmind Medicine stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $0.12, for a total value of $27,022.92. Following the sale, the insider directly owned 1,838,075 shares in the company, valued at $220,569. This trade represents a 10.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Clearmind Medicine to a “sell” rating in a report on Saturday, May 23rd.

About Clearmind Medicine

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.